Tumor response to neoadjuvant chemotherapy predicts long‐term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial
Authors:
- 21 December 2016
- Vol. 123 (9) , 1643-1652
Abstract
BACKGROUND: Tumor response to neoadjuvant chemotherapy using the regimen of cisplatin and 5‐fluorouracil could define high‐risk patients with locoregionally advanced nasopharyngeal carcinoma (NPC). However, the regimen of docetaxel, cisplatin, and 5‐fluorouracil (TPF) appears to be more effective than the regimen of cisplatin and 5‐fluorouracil. Therefore, one needs to redefine the high‐risk subpopulation of patients receiving neoadjuvant chemotherapy with TPF.METHODS: A total of 231 patients from a randomized phase 3 trial with American Joint Committee on Cancer/International Union Against Cancer stage III to stage IVB NPC (except T3‐T4N0 disease) who were receiving treatment with the TPF regimen were enrolled. Patient survival rates between different groups were compared.RESULTS: Of the 231 patients, the overall response to neoadjuvant chemotherapy was a complete response (CR) for 26 (11.3%), a partial response (PR) for 184 patients (79.6%), and stable disease (SD) for 21 patients (9.1%). Univariate analysis revealed the 3‐year failure‐free survival (FFS) rates in the CR (88.5% vs 61.9%; P =.017) and PR (81.2% vs 61.9%; P = .01) groups, and the 3‐year overall survival rates for the CR (96.2% vs 76.2%; P =.048) and PR (93.4% vs 76.2%; P =.025) groups were obviously higher compared with that of the SD group. In multivariate analysis, CR was established as a favorable prognostic factor for FFS (hazard ratio [HR], 0.210; 95% confidence interval [95% CI], 0.057‐0.779 [P =.02]), and PR for FFS (HR, 0.447; 95% CI, 0.213‐0.936 [P =.033]) and OS (HR, 0.361; 95% CI, 0.132‐0.986 [P =.047]) when compared with SD. No survival difference was observed between the CR and PR groups.CONCLUSIONS: Tumor response to TPF may be a properly powerful prognosis predictor and help to develop individualized treatment strategies for patients with locoregionally advanced NPC. Cancer 2017;123:1643–1652. © 2017 American Cancer Society.Keywords
Funding Information
- Sun Yat-Sen University Clinical Research 5010 Program (2007037)
- Health and Medical Collaborative Innovation Project of Guangzhou City, China (201400000001)
- Planned Science and Technology Project of Guangdong Province (2013B020400004)
- National Science and Technology Pillar Program during the Twelfth Five-Year Plan Period (2014BAI09B10)
This publication has 42 references indexed in Scilit:
- A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinomaOral Oncology, 2013
- Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathwaysOncogene, 2012
- Increased expression of annexin I is associated with drug‐resistance in nasopharyngeal carcinoma and other solid tumorsProteomics – Clinical Applications, 2009
- Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal CarcinomaJournal of Clinical Oncology, 2009
- Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapyCancer, 2006
- Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal CarcinomaJNCI: Journal of the National Cancer Institute, 2005
- Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNAJournal of Clinical Oncology, 2004
- Prognostic Value of Multidrug Resistance 1, Glutathione-S-Transferase-π and p53 in Advanced Nasopharyngeal Carcinoma Treated with Systemic ChemotherapyOncology, 2002
- PROGNOSTIC VALUE OF DAY 14 BLAST PERCENTAGE AND THE ABSOLUTE BLAST INDEX IN BONE MARROW OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIAPediatric Hematology and Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000